Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

FDA Apporoves ‘Alhemo’ to Help Hemophilia Patients Manage Bleeding

Daniel Kim Views  

Novo Nordisk\'s hemophilia treatment has received approval from the U.S. FDA. / Medical Today
Novo Nordisk’s hemophilia treatment has received approval from the U.S. FDA. / Medical Today

Novo Nordisk’s hemophilia treatment has received approval from the U.S. Food and Drug Administration (FDA). The FDA has approved Novo Nordisk’s Alhemo to reduce bleeding in hemophilia patients.

Hemophilia is a condition that impairs the body’s ability to form blood clots, leading to prolonged bleeding episodes. In the United States, approximately 33,000 individuals are affected by this disorder.

Current hemophilia treatments primarily involve replacement therapy, which administers clotting factors to normalize the blood clotting process. However, 30% of patients with hemophilia A and 5% to 15% of those with hemophilia B develop antibodies against these clotting factors, reducing the effectiveness of traditional replacement therapy.

Alhemo is approved for use in adolescents and adults aged 12 and older who have developed such antibodies. Administered via subcutaneous injection, Alhemo aims to enhance the effectiveness of replacement therapy and reduce bleeding.

Meanwhile, current hemophilia treatments include Pfizer’s injection HYMPAVZI, approved in October, and several gene therapies.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Hate the Dentist? You Still Need This One Crucial Cleaning
  • How People With 12% Body Fat Stay Lean—Without Diets or Crazy Workouts
  • Shocking Study Finds Cancer-Causing Arsenic in Brown Rice
  • Forget the Scale—This Is the Fat That Really Matters
  • Fasted Workouts: Why Skipping Breakfast Might Boost Your Fitness
  • Doctors Urge Caution as Killer Bacteria Found in Warm Seawater

Share it on...